BioDelivery Sciences International, Inc.

BDSI

US09060J1060

BioDelivery Sciences International, Inc. Provides Earnings Guidance for the Year 2021

November 03, 2021 at 12:00 pm

BioDelivery Sciences International, Inc. provided earnings guidance for the year 2021. For the year, the company is lowering its full year 2021 total net revenue guidance range to $162 - $167 million from $170 - $180 million previously communicated. BDSI now expects BELBUCA net sales for 2021 to be in the range of $144 - $148 million dollars.

Latest news about BioDelivery Sciences International, Inc.

Tranche Update on BioDelivery Sciences International, Inc.'s Equity Buyback Plan announced on November 4, 2020.	05/05/22	CI
Collegium Pharmaceutical Completes Acquisition of BioDelivery Sciences	23/03/22	MT
BioDelivery Sciences International, Inc.(NasdaqGS:BDSI) dropped from NASDAQ Composite Index	22/03/22	CI
BioDelivery Sciences International, Inc.(NasdaqGS:BDSI) dropped from S&P Global BMI Index	21/03/22	CI
BioDelivery Sciences International, Inc.(NasdaqGS:BDSI) dropped from S&P TMI Index	21/03/22	CI
Collegium Pharmaceutical, Inc. completed the acquisition of BioDelivery Sciences International, Inc. for approximately $670 million.	20/03/22	CI
BioDelivery Sciences International, Inc.(NasdaqGS:BDSI) dropped from NASDAQ Biotechnology Index	18/03/22	CI
Tranche Update on BioDelivery Sciences International, Inc.'s Equity Buyback Plan announced on November 4, 2020.	09/03/22	CI
BioDelivery Sciences International, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	09/03/22	CI
Truist Securities Downgrades BioDelivery Sciences International to Hold From Buy, Adjusts Price Target to $5.60 From $7	28/02/22	MT
BioDelivery Sciences International Launches Oral Solution for Acute Treatment of Migraine in US	24/02/22	MT
Biodelivery Sciences International Announces ELYXYB Is Now Available in the U.S. for the Acute Treatment of Migraine	24/02/22	CI
Northland Downgrades BioDelivery Sciences International to Market Perform From Outperform, Lowers Price Target to $5.60 From $7	15/02/22	MT
Piper Sandler Downgrades BioDelivery Sciences International to Neutral From Overweight, Lifts Price Target to $5.60 From $5	15/02/22	MT
Collegium Pharmaceutical to Acquire BioDelivery Sciences in All-Cash Deal; Shares Jump	14/02/22	MT
Top Midday Gainers	14/02/22	MT
Wall Street Set for Losses Amid Ukraine Crisis	14/02/22	MT
BioPharma Credit To Provide $650 Million Loan To Collegium For BioDelivery Acquisition	14/02/22	MT
Transcript : BioDelivery Sciences International, Inc., Collegium Pharmaceutical, Inc. - M&A Call	14/02/22
Top Premarket Gainers	14/02/22	MT
Collegium Pharmaceutical to Acquire BioDelivery Sciences in All-Cash Deal	14/02/22	MT
Collegium Pharmaceutical, Inc. entered into an agreement to acquire BioDelivery Sciences International, Inc. for approximately $580 million.	13/02/22	CI
BioDelivery Sciences Shares Soar Amid Higher-Than-Average Volumes	24/01/22	MT
HC Wainwright Adjusts BioDelivery Sciences International Price Target to $4.50 From $4, Maintains Neutral Rating	21/01/22	MT
BioDelivery Sciences International, Inc. Revises Earnings Guidance for the Full Year 2021	20/01/22	CI

Chart BioDelivery Sciences International, Inc.

Duration

Period

Chart BioDelivery Sciences International, Inc.

More charts

Company Profile

BioDelivery Sciences International, Inc. is a specialty pharmaceutical company. The Company focuses on delivering therapies for individuals living with serious and debilitating chronic conditions. The Company builts a portfolio of products that includes utilizing its BioErodible MucoAdhesive (BEMA), drug-delivery technology to develop and commercialize new applications of therapies aimed at addressing important unmet medical needs. BEMA drug delivery technology consists of a small, bi-layered erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company's product candidates include BELBUCA (buprenorphine buccal film), CIII, for chronic pain; Symproic (naldemedine), for opioid induced constipation; ELYXYB (celecoxib oral solution) for acute treatment of migraine, and ONSOLIS (fentanyl buccal soluble film) for breakthrough cancer pain.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+38.51%	727B
NOVO NORDISK A/S	+31.74%	594B
JOHNSON & JOHNSON	-6.23%	354B
MERCK & CO., INC.	+18.78%	328B
ABBVIE INC.	+1.35%	277B
ASTRAZENECA PLC	+16.00%	243B
NOVARTIS AG	+8.44%	205B
ROCHE HOLDING AG	-5.97%	203B
AMGEN INC.	+6.19%	164B

Other Pharmaceuticals